[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fapi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fapi":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,80,110,137,158,183,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100643410","68ga-fapi-psma-pet-imaging-for-the-diagnosis-of-solid-tumors-100643410",false,"NCT07639801","68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors","Evaluation of Dual-Targeted 68Ga-FAPI-PSMA PET\u002FCT for the Diagnosis and Staging of Solid Tumors","Inclusion Criteria:\n\n* Age 18-75 years\n\n  * Patients with suspected or confirmed solid tumors (e.g., prostate cancer, hepatocellular carcinoma, ovarian cancer, or endometrial cancer)\n  * Patients scheduled to undergo tumor biopsy or surgical treatment within 2 months\n  * ECOG performance status of 0 or 1\n  * Expected survival of at least 12 weeks\n  * Adequate hematologic and organ function:\n  * White blood cell count ≥ 4.0 × 10\\^9\u002FL or neutrophils ≥ 1.5 × 10\\^9\u002FL\n  * Platelet count ≥ 100 × 10\\^9\u002FL\n  * Hemoglobin ≥ 90 g\u002FL\n  * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n  * ALT\u002FAST ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)\n  * Creatinine ≤ 1.5 × ULN\n  * At least one measurable lesion according to RECIST 1.1 criteria\n  * Ability to understand the study procedures and willingness to sign written informed consent\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction\n* Inability to remain in a supine position for approximately 30 minutes during PET\u002FCT scanning\n* Refusal or inability to participate in the clinical study\n* Claustrophobia or severe psychiatric disorders that would interfere with imaging procedures\n* Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors. Fibroblast activation protein (FAP) and prostate-specific membrane antigen (PSMA) are two important molecular targets that are highly expressed in tumor cells or the tumor microenvironment. Combining these two targets into a single imaging probe may improve the sensitivity and accuracy of tumor detection.\n\nIn this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET\u002FCT imaging using 68Ga-FAPI-PSMA. The imaging results will be compared with standard PET tracers such as 68Ga-PSMA-617 or 68Ga-FAPI-04. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-FAPI-PSMA PET\u002FCT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.",[27,28,29,30,31,32,33],"Prostate Cancer","Hepatocellular Carcinoma","Ovarian Cancer","Solid Tumors","Endometrial Cancer","FAPI","PSMA","NOT_YET_RECRUITING","2026-06-06",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2026-12-31",{"name":44,"class":45},"Peking University Cancer Hospital & Institute","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100600523","phase-2-pancreatic-cancer-diagnosis-with-fapi-pet-imaging-100600523","NCT07098598","Pancreatic Cancer Diagnosis With FAPI-PET Imaging","Diagnostic Efficacy of 18F-FAPI-74 PET\u002FCT in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Suspected primary or recurrent pancreatic cancer\n* Subjects must be male or female aged 18-85 years.\n* WHO performance score 0-2.\n* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.\n* Study subject is not able to understand the purpose of the study.\n* Medical conditions prohibiting whole-body PET\u002FCT imaging.","85 Years",{"count":55,"type":21},100,[57,58],"PHASE2","PHASE3","Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET\u002FCT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexpressed in cancer-associated fibroblasts. It presents a potential new PET imagining tool.\n\nThe objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET\u002FCT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET\u002FCT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.",[61,62,32,63,64,65,66,67],"Positron Emission Tomography","Pancreatic Cancer","Diagnostics","Recurrent Pancreatic Cancer","Oncologic Surgery","Imaging, Diagnostic","Staging","RECRUITING","2025-07-31",{"date":71,"type":38},"2025-08-01",{"date":73,"type":38},"2024-10-09",{"date":75,"type":21},"2026-10",{"name":77,"class":78},"Turku University Hospital","OTHER_GOV",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":79},"100576806","phase-2-the-diagnostic-accuracy-and-clinical-value-of-fapi-pet-in-pleural-mesothelioma-100576806","NCT06790082","The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma","FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation","FAPI-PM","Inclusion Criteria:\n\n* Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy.\n* Undergone\u002Fundergoing FDG PET\u002FCT as part of the diagnostic workup of a suspicious PM lesion.\n* Considered physically and mentally able to participate in the research project.\n* Understands the study subject information and able to consent to project participation.\n* 18-years or older\n\nExclusion Criteria:\n\n* Patients with an imminent need for surgery or in an emergency\n* Known concurrent other malignancy with active treatment within the last 1 year; non-melanoma skin cancer and cervical cancer in situ are exempt.\n* Pregnant or breastfeeding women.\n* Fertile women (women of childbearing potential) who could - theoretically - be pregnant (i.e., unknown pregnancy status).\n\nFertile women will be tested for pregnancy (by urine humane choriogonadotropin (HCG) or serum HCG) within 48h before FAPI PET\u002FCTs, both at primary staging and restaging. Study subjects can participate in the study if the pregnancy test is negative (i.e., not pregnant).\n\n* Subjects unable to undergo PET\u002FCT: e.g., weighing more than 180 kg (weight limit scanner), unable to fit within the imaging gantry, inability to remain still for the duration of the examination, or with known severe claustrophobia unresponsive to oral anxiolytics or severe fear of needles.\n* Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease the reliability of data, achievement of study objectives or completing the study.\n* History of allergic reactions \u002F hypersensitivity attributed to \\[18F\\]FDG or FAPI-tracers.",{"count":89,"type":21},70,[57],"Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET\u002FCT at primary staging.\n\nThe FAPI PET\u002FCT results will be compared to conventional imaging (including FDG PET\u002FCT). The diagnostic accuracy will be determined with histopathology as reference standard.\n\nFor patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET\u002FCT and an additional FDG PET\u002FCT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET\u002FCT in response evaluation will be investigated.\n\nAll study specific analyzes will be blinded and will not influence the patient management \u002F treatment.",[93,94,95,32,96],"Pleural Mesothelioma","Pleural Diseases","Cancer","Fibroblast Activation Protein Inhibitor",[32,98,99,93,100],"68Ga-FAPI-46","PET\u002FCT","FDG PET\u002FCT","2025-07-01",{"date":103,"type":38},"2025-07-03",{"date":105,"type":38},"2025-01-29",{"date":107,"type":21},"2037-04-30",{"name":109,"class":45},"Aalborg University Hospital",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":79},"100588757","evaluation-of-intestinal-lesions-and-disease-activity-in-inflammatory-bowel-disease-based-on-18f-fapi-pet-imaging-100588757","NCT06945549","Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging","IBD，18F-FAPI","Inclusion Criteria:\n\n* Patients diagnosed with IBD according to clinical, imaging, endoscopic, and histopathological criteria;\n* Patients ≥18 years old;\n* 18F-FAPI PET\u002FCT intestinal imaging, conventional endoscopic and enhanced CT were performed within 1 week;\n* Intestinal segment matching was evaluated by endoscopy and imaging;\n* Patients voluntarily participate and sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients;\n* Imaging images are of poor quality and cannot be used for diagnosis and evaluation;\n* Patients with contraindications for endoscopic or CT examination.",{"count":118,"type":21},30,"OBSERVATIONAL","The goal of this observational study is to evaluate the role and effect of 18F-FAPI PET imaging in the identification of intestinal lesions and the assessment of disease activity in inflammatory bowel disease. The main question it aims to answer is:\n\nCan 18F-FAPI PET imaging effectively identify intestinal lesions in inflammatory bowel disease and accurately assess disease activity? Colonoscopy, enhanced abdominal CT, and 18F-FAPI intestinal imaging were completed within 1 week, and major adverse outcomes (MAO) were followed up 12 months after enrollment.\n\nLast updated on March 25, 2025",[122,123,32],"Inflammatory Bowel Disease (IBD)","Disease Activity",[125,126,127],"Inflammatory bowel disease","18F-FAPI PET","disease activity","2025-06-25",{"date":130,"type":38},"2025-06-29",{"date":132,"type":38},"2025-04-25",{"date":134,"type":21},"2027-12-31",{"name":136,"class":45},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":79},"100441609","exploring-the-application-value-of-pet-molecular-imaging-targeting-fap-in-oral-squamous-cell-carcinoma-100441609","NCT05030597","Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma","FAPI-OSCC","Inclusion Criteria:\n\n1. Voluntary participation with signed informed consent;\n2. Aged 18\\~70 years;\n3. Clinically highly suspected oral cancer and recurrence after treatment (Newly diagnosed patients: Scheduled for surgery or neoadjuvant therapy followed by surgery);\n4. Ability to complete baseline and follow-up PET\u002FCT (Follow-up FAPI PET\u002FCT applies only to locally advanced patients undergoing neoadjuvant therapy.).\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, or women planning pregnancy during the trial period;\n2. Known hypersensitivity to FAPI, FDG, or their components, or history of severe allergic reactions;\n3. People with poor general condition, their heart, lung, liver, kidney and other important organ functions cannot tolerate surgery;\n4. Before the injection of 18F-FDG, the fasting blood glucose level exceeded 11.0 mmol\u002FL;\n5. Claustrophobia or inability to tolerate PET\u002FCT imaging (Those who cannot tolerate lying supine for 15\\~30 minutes.);\n6. Participation in another interventional clinical trial within 30 days prior to enrollment, or planned participation during this study.","70 Years",{"count":55,"type":21},"In this prospective study, the investigators will use integrated PET\u002FCT with the agent 68Ga-FAPI and conventional imaging agent 18F-FDG to explore the application value of FAP-targeted molecular imaging in the diagnosis and staging for oral cancer. This study also aims to explore the application value of FAPI imaging in evaluating treatment response for oral cancer.",[99,32,148],"Oral Cancer","2025-05-21",{"date":151,"type":38},"2025-05-28",{"date":153,"type":38},"2021-09-15",{"date":155,"type":21},"2025-12-31",{"name":157,"class":45},"Zhongnan Hospital",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":4},"100589697","the-value-of-68ga-fapi-petct-for-evaluating-peritoneal-treatment-response-100589697","NCT06957782","The Value of 68Ga-FAPI PET\u002FCT for Evaluating Peritoneal Treatment Response","INTERACT-FAPI","Inclusion Criteria:\n\n* A planned start of repeated IP chemotherapy (with or without the combination of systemic chemotherapy) for macroscopic peritoneal metastases;\n* WHO-performance score of 0 to 1;\n* Aged 18 years or older;\n* Written informed consent according to the ICH-GCP and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Impaired renal function, defined as eGFR \\\u003C25 ml\u002Fmin\u002F1,73 m2. An exception can be made in consultation with the treating physician;\n* Pregnancy\u002Fbreastfeeding. For the latter, temporary discontinuation may be considered;\n* Known allergic reaction to therapeutic radiopharmaceuticals;\n* Inability to lie still on the back for the duration of PET-CT;\n* Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient's experience of study burden (such as non-suppressible claustrophobia).",{"count":166,"type":21},16,[24],"Peritoneal metastases (PM), commonly originating from gastrointestinal and ovarian cancers, are associated with a poor prognosis and limited treatment options due to the diffuse nature of the disease and the inability of systemic chemotherapy to adequately penetrate the peritoneal surface. Intraperitoneal (IP) chemotherapy has emerged as a potential treatment modality for patients with extensive PM, allowing for higher local drug concentrations while minimizing systemic toxicity. However, current response evaluation methods, such as CT scans, have low sensitivity for detecting PM, and second-look laparoscopy, although more accurate, is invasive and unsuitable for repeated assessments. The ⁶⁸Ga-FAPI PET\u002FCT scan offers a promising non-invasive alternative for assessing peritoneal response to IP chemotherapy. This imaging technique targets the fibroblast activation protein, which is overexpressed in cancer-associated fibroblasts within the tumor microenvironment. Early studies have shown that ⁶⁸Ga-FAPI PET\u002FCT is a highly sensitive too in detecting peritoneal metastases. Given these advantages, the investigators hypothesize that ⁶⁸Ga-FAPI PET\u002FCT could improve the evaluation of treatment response in patients undergoing IP chemotherapy for PM, offering a non-invasive and accurate alternative to current methods. The primary objective of this study is to investigate the accuracy of ⁶⁸Ga-FAPI PET\u002FCT for evaluating peritoneal response in patients with peritoneal metastases undergoing repeated IP chemotherapy.",[170,32],"Peritoneal Metastasis",[172,173,32,99],"Peritoneal metastasis","Intraperitoneal","2025-05-06",{"date":176,"type":38},"2025-05-09",{"date":178,"type":21},"2025-09",{"date":180,"type":21},"2027-03",{"name":182,"class":45},"Erasmus Medical Center",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":191,"sex":16,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100586138","from-inflammation-to-remodelling-towards-personalized-diagnosis-in-post-acute-sequelae-of-covid-19-100586138","NCT06911476","From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","From Inflammation Biomarkers to Remoddeling (FAPI PET\u002FCT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19","LIBERATE","Inclusion Criteria:\n\n\\- Self-reported complaints of dyspnea or fatigue \\> 3 months after SARS-CoV-2 infection confirmed with PCR, serology test or COVID-19 Reporting and Data System (CO-RADS) score 4\u002F5.\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or feeling of inability to tolerate supine position for the PET\u002FCT scans.\n* Individuals who are pregnant or currently breastfeeding are not eligible to participate",true,"20 Years",{"count":194,"type":21},60,"Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that \\[68Ga\\]FAPI Positron Emission Tomography-Computed Tomography (PET\u002FCT) imaging shows potential for diagnosis and molecular understanding of this syndrome. We have previously shown that fibroblast activation protein (FAP) can be imaged in the lung, muscle and nasopharynx of long COVID patients (with dyspnea and fatigue). However, these preliminary data are derived from a selective group of patients with long COVID after critical COVID-19. We aim to explore the generalizability of these findings in patients with long COVID with dyspnea and fatigue, irrespective of the severity of their acute SARS-CoV-2 infection.\n\nPrimary objective: To assess if pulmonary fibroblast activity, measured by \\[68Ga\\]FAPI-46 PET\u002FCT, is higher in patients with current long COVID dyspnea and fatigue compared to patients with resolved complaints.\n\nStudy design: This is a ZonMw funded single centre prospective observational cohort study of long COVID-19 patients with dyspnea and fatigue.\n\nStudy population: We will recruit 60 adult long COVID patients (aged \\>20 years) of which 30 have complaints of dyspnea and fatigue and compare them to 30 patients with resolved complaints and healthy controls.\n\nMain study parameters\u002Fendpoints: The primary endpoint is FAP expression in the lung measured by \\[68Ga\\]FAPI-46 PET\u002FCT. Secondary endpoints are the expression of FAP in other tissues (muscle) and the relation between FAP and inflammation and remodelling biomarkers in various biological samples (e.g. serum\u002Fnasal epithelium).\n\nStudy procedures: In a single visit day the following data and samples will be collected: questionnaires, a lung function test, 6-minute walking test, blood samples, nose swabs, \\[68Ga\\]FAPI PET\u002FCT scan and HRCT scan. When increased \\[68Ga\\]FAPI uptake is measured in the muscles a muscle biopsy will be performed as well.",[197,198,199,200,32,201,96,202,203],"PASC Post Acute Sequelae of COVID 19","Long COVID","Long Covid-19","PASC","FAP","Fibroblast","Restrictive Lung Disease","2025-04-03",{"date":206,"type":38},"2025-04-04",{"date":208,"type":21},"2025-05",{"date":210,"type":21},"2025-12",{"name":212,"class":45},"University Medical Center Groningen",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":228,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":79},"100586103","68ga-fapi-46-in-staging-of-pancreatic-adenocarcinoma-100586103","NCT06911021","68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma","68Ga-FAPI-46 PET\u002FCT for Tumor Fibroblast Imaging to Refine Tumor Assessment and Therapeutic Strategies of Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥18 years.\n* Karnofsky index ≥80%.\n* Operable or operable borderline tumor after neoadjuvant chemotherapy response\n* Planned surgical tumor resection.\n* SOC imaging (ceCT and MRI) performed as pre-surgery exams.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Claustrophobia.\n* Severe renal insufficiency (GFR\\\u003C30 mL\u002Fmin\u002F1.73m²).\n* Liver enzymes (ALAT, ASAT \\>5× the upper limit).\n* Bilirubin \\>3× the upper limit.\n* Hemoglobin \\\u003C8 g\u002FdL.\n* Absolute neutrophil count \\\u003C1000\u002Fmm³.\n* Platelets \\\u003C75,000\u002FµL.\n* Inability to give informed consent or follow study procedures.\n* The patient refuses to receive information regarding incidental findings.",{"count":20,"type":21},[24],"This clinical study investigates the use of a new imaging technique called 68Ga-FAPI-46 PET\u002FCT in people with pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its rapid progression, late diagnosis, and poor survival rate. One of the main challenges with pancreatic cancer is that standard images like MRI and CT, while helpful, are not always able to clearly show how far the cancer has spread or where exactly the tumor ends. This can make surgery and treatment planning more difficult and less precise.\n\nThe new image technique being studied, 68Ga-FAPI-46 PET\u002FCT, works by injecting a small and safe amount of a radioactive substance into a vein. This substance travels through the body and attaches to a specific protein called FAP, which is found in large amounts in the tissue that surrounds many pancreatic tumors. By sticking to this protein, the tracer highlights not only the tumor but also the surrounding area that may be affected by the cancer. This results in very detailed images that may show the tumor more clearly than other techniques.\n\nEach participant in the study will receive a single injection of the tracer, and about an hour later they will have the PET\u002FCT scan. The scan itself is quick, painless, and non-invasive, and takes about 20 minutes. A few days later, participants will receive a follow-up phone call to check if they experienced any side effects, though previous studies with over 1,000 people have shown the tracer to be very safe.\n\nThe purpose of the study is to find out whether this new technique provides more useful and accurate information than the standard images currently used. It may help better detect the size of the tumor, see if it has spread to other parts of the body, and give doctors a clearer idea of how to plan surgery. This could make it easier to remove the tumor completely and choose the most effective treatment for each patient.\n\nThis pilot study is being conducted at Lausanne University Hospital (CHUV) with 20 adult participants over two years. CHUV is the first hospital in Switzerland to offer this kind of scan. If the study is successful, this scan may become a regular part of care for people with pancreatic cancer and could also be used in other cancers in the future.",[224,225,32,226,227],"Pancreatic Adenocarcinoma","PET \u002F CT","Surgical Oncology","Molecular Imaging",[229,230,231,232,233],"Novel imaging in pancreatic cancer","Fibroblast activation protein imaging","Cancer-associated fibroblasts","PET\u002FCT and pancreatic tumor","Tumor microenvironment imaging","2025-03-28",{"date":206,"type":38},{"date":237,"type":21},"2025-05-01",{"date":134,"type":21},{"name":240,"class":45},"Centre Hospitalier Universitaire Vaudois"]